GLP-1: A Leading Hotspot in Drug Discovery and Design
mybcs
The Rising Global Demand for GLP-1 Therapies
As global rates of diabetes and obesity continue to climb, GLP-1 receptor agonists (GLP-1 RAs) have attracted tremendous attention for their remarkable glucose-lowering and weight-reducing effects. However, all currently approved GLP-1 RAs-such as semaglutide and tirzepatide-are peptide-based drugs, predominantly administered by injection. Even the few available oral formulations have low bioavailability and require strict dietary restrictions during.